Why the study?
Does CpG-ODN C274 attenuate pathological cardiac hypertrophy and prevent heart failure in preclinical models?
Population
In vitro cardiac myocytes and in vivo mouse models of isoproterenol-induced pathological cardiac hypertrophy
Comparison
CpG-ODN C274 vs Isoproterenol alone (control)
Design
Preclinical
Authors
Loading...
Hypothesis-generating for CpG-ODNs in cardiac hypertrophy; leaves open translation to human heart failure therapy.
Does CpG-ODN C274 attenuate pathological cardiac hypertrophy and prevent heart failure in preclinical models?
CpG-ODNs represent a novel cardioprotective agent that attenuates pathological cardiac hypertrophy and prevents heart failure via PI3Kα-Akt signaling in preclinical models.
Yang et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: